News Releases

2019-11/08
United BioPharma Receives US FDA Approval for UB-221 Phase 1 IND for Chronic Spontaneous Urticaria
1
2019-10/07
PharmaBoardRoom interview of Dr. Chang Yi Wang, Chairperson and Chief Scientific Officer of United Biopharma (UBP)
2
2019-09/02
United BioPharma successfully completes Taiwan FDA GMP inspection for its 2000L commercial scale manufacturing facility
3
2019-05/14
United BioPharma Receives China NMPA Approval for UB-421 Phase 3 ART-Substitution Trial in HIV-infected Patients
4
2019-04/18
Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption(N Engl J Med 2019; 380:1535-1545)
5
2019-04/18
United BioPharma Announces Publication of Breakthrough HIV Clinical Trial Data in the New England Journal of Medicine
6
2019-04/18
How an Experimental Injection Could Revolutionize HIV Treatment
7
2019-06/11
United BioPharma Receives US FDA Approval for UB-621 Phase 2 Trial in Recurrent Genital Herpes Patients
8
2019-05/21
United Biopharma obtains approval from the U.S. FDA to conduct a clinical trial with UB-421 in Patients with Multi-Drug Resistance HIV-1 infection
9
2019-11/08
United BioPharma Receives US FDA Approval for UB-221 Phase 1 IND for Chronic Spontaneous Urticaria
1
2019-10/07
PharmaBoardRoom interview of Dr. Chang Yi Wang, Chairperson and Chief Scientific Officer of United Biopharma (UBP)
2
2019-09/02
United BioPharma successfully completes Taiwan FDA GMP inspection for its 2000L commercial scale manufacturing facility
3
2019-05/14
United BioPharma Receives China NMPA Approval for UB-421 Phase 3 ART-Substitution Trial in HIV-infected Patients
4
2019-04/18
Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption(N Engl J Med 2019; 380:1535-1545)
5
2019-04/18
United BioPharma Announces Publication of Breakthrough HIV Clinical Trial Data in the New England Journal of Medicine
6
2019-04/18
How an Experimental Injection Could Revolutionize HIV Treatment
7
2019-06/11
United BioPharma Receives US FDA Approval for UB-621 Phase 2 Trial in Recurrent Genital Herpes Patients
8
2019-05/21
United Biopharma obtains approval from the U.S. FDA to conduct a clinical trial with UB-421 in Patients with Multi-Drug Resistance HIV-1 infection
9
IND submission of a phase I clinical trial for UB-621, an Anti-HSV-gD antibody, was approved by Taiwan Food and Drug Administration (TFDA) 2015-11/15
United BioPharma received approval for UB-421 Phase II clinical trial for HAART substitution treatment in treatment stabilized HIV patients from Taiwan Food and Drug Administration (TFDA) 2015-06/15
Filed an IND submission of a phase II clinical trial for HAART substitution therapy in treatment stabilized HIV patients with Taiwan Food and Drug Administration (TFDA) 2015-02/15
UB-421 product received Gold Medal award for 2014 Pharmaceutical Technology Research and Development jointly given by Ministry of Economic Affairs and Minitry of Health, Taiwan 2014-12/15
Filed an IND submission of a phase I clinical trial for UB-621, an anti-HSV-gD antibody, with Taiwan Food and Drug Administration (TFDA) 2014-12/15
United BioPharma Licenses Innovative Antibody Drug 8D6 for Asthma and Allergy Treatment from Academia Sinica 2014-12/14
Completion of phase IIa clinical trial of UB-421, the anti-CD4 antibody for treatment in HIV treatment naïve patients 2014-11/15
United BioPharma was selected as the recipient by government’s Industrial Cooperation Program (ICP) to carry out the technology transfer of Single Use Disposal system in biological manufacturing from GE Healthcare 2014-09/15
anti-CD4 mAb drug candidate UB-421 won the Gold Medal Prize for Innovative Research and Development given by Taipei City government for 2014 Taipei Biotechnology Award 2014-09/15
United BioPharma was listed on the Taiwan Emerging Stock Market (Stock code : 6471) 2014-09/13